Dr. Hong Discusses IPI-549 in Advanced Solid Tumors

Video
Conference|SITC Meeting

David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses IPI-549 during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses IPI-549 during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

IPI-549 is an oral selective P13K-gamma inhibitor targeting tumor macrophages. Hong presented on the monotherapy dose-escalation clinical and translational data from a first-in-human study of this inhibitor in advanced solid tumors during the meeting.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Related Content
Diwakar Davar, MD, MSc

Cobolimab/Dostarlimab Combination Shows Initial Efficacy and Safety Signals in Advanced NSCLC

January 10th 2024
Article
Christopher T. Chen, MD

Camidanlumab Tesirine Plus Pembrolizumab Produces Responses But Increases Immune Toxicities in Select Solid Tumors

January 9th 2024
Article
Updates and Advances in Early Stage Breast Cancer

Updates and Advances in Early Stage Breast Cancer

April 5th 2023
Article
Sylvie Rottey, MD, PhD, of Ghent University Hospital in Belgium

Cabozantinib/Atezolizumab Elicits Durable, Tolerable Clinical Activity in Advanced HNSCC

November 29th 2022
Article
PDS0101 Plus Chemoradiation Elicits 100% ORR in High-Risk Locally Advanced Cervical Cancer

PDS0101 Plus Chemoradiation Elicits 100% ORR in High-Risk Locally Advanced Cervical Cancer

November 23rd 2022
Article
Salah-Eddine Bentebibel, PhD

Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma

November 16th 2022
Article